Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eprosartan (SKF-108566J free base) 是一种具有选择性和竞争性的非肽类血管紧张素II受体拮抗剂,对AT1受体亚型具有高亲和力,可用作降压剂。Eprosartan 对血管紧张素 II 受体有抑制作用,在大鼠和人类肾上腺皮质膜中的 IC50 值分别为 9.2 nM 和 3.9 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,080 | 现货 | ||
50 mg | ¥ 1,630 | 现货 | ||
100 mg | ¥ 2,430 | 现货 | ||
500 mg | ¥ 5,760 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | Eprosartan (SKF-108566J free base) is a selective and competitive nonpeptide angiotensin II receptor antagonist with high affinity for AT1 receptor subtypes and can be used as an antihypertensive agent.Eprosartan has an inhibitory effect on angiotensin II receptor, with IC50 values of 9.2 nM and 3.9 nM in rat and human adrenocortical membranes, respectively. The IC50 values of Eprosartan in rat and human adrenocortical membranes were 9.2 nM and 3.9 nM, respectively. |
靶点活性 | Mesenteric artery membranes (rat):1.5 nM, [125I] bnding to human liver membranes:1.7 nM |
体外活性 | Eprosartan (SKF-108566J) inhibits [125I]AII binding to human liver membranes with an IC50 of 1.7 nM and to rat mesenteric artery membranes with an IC50 of 1.5 nM. In rabbit aortic smooth muscle cells, Eprosartan causes a concentration-dependent inhibition of AII-induced increases in intracellular Ca2+ levels[1] |
体内活性 | In conscious normotensive rats, intravenous administration of Eprosartan (0.01-0.3 mg/kg) produced dose-dependent parallel shifts in the AII pressor dose-response curve. Intragastric or intraduodenal administration of Eprosartan (3-10 mg/kg) to conscious normotensive rats resulted in a dose-dependent inhibition of the pressor response to AII (250 ng/kg, i.v.). Significant inhibition of the pressor response to AII was observed for 3 hours at a dose of 10 mg/kg, intraduodenally[1]. |
别名 | KF-108566J free base, Teveten |
分子量 | 424.51 |
分子式 | C23H24N2O4S |
CAS No. | 133040-01-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (129.56 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3557 mL | 11.7783 mL | 23.5566 mL | 58.8914 mL |
5 mM | 0.4711 mL | 2.3557 mL | 4.7113 mL | 11.7783 mL | |
10 mM | 0.2356 mL | 1.1778 mL | 2.3557 mL | 5.8891 mL | |
20 mM | 0.1178 mL | 0.5889 mL | 1.1778 mL | 2.9446 mL | |
50 mM | 0.0471 mL | 0.2356 mL | 0.4711 mL | 1.1778 mL | |
100 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.5889 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Eprosartan 133040-01-4 Endocrinology/Hormones RAAS KF-108566J KF-108566J free base Teveten Inhibitor inhibitor inhibit